SCHEMBL14633669

SCHEMBL14633669

Cc1cc(-c2cnc(N)nc2Nc2n[nH]c3ncc(F)cc23)cc(S(=O)(=O)C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.38
RIPK2 O43353 3/20 0.37
KCNH2 Q12809 3/20 0.37
GAK O14976 1/20 0.37
LCK P06239 1/20 0.37
TGFBR1 P36897 1/20 0.37
MAPK14 Q16539 1/20 0.37
RIPK3 Q9Y572 1/20 0.37
PDGFRB P09619 2/20 0.34
FGFR1 P11362 2/20 0.34
PDGFRA P16234 2/20 0.34
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
SRC P12931 1/20 0.32
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14633761 0.90 RIPK2 (0.36) PIK3CARIPK2KCNH2GAKLCK
SCHEMBL14634007 0.80 PIK3CA (0.39) PIK3CARIPK2MAPK14PDGFRBFGFR1
SCHEMBL14633930 0.78 PIK3CA (0.42) PIK3CAMAPK14GSK3AGSK3BALOX5AP
SCHEMBL2466795 0.73 FADS1 (0.45) PIK3CARIPK2KCNH2GAKLCK
SCHEMBL14633486 0.73 PIK3CA (0.41) PIK3CAGSK3AGSK3BALOX5APFEN1
SCHEMBL2516608 0.73 RIPK2 (0.42) RIPK2KCNH2GAKLCKTGFBR1
SCHEMBL14634220 0.72 ALOX5AP (0.33) PIK3CAPDGFRBFGFR1PDGFRAALOX5AP
SCHEMBL2470683 0.71 GSK3A (0.39) PIK3CALCKMAPK14PDGFRBFGFR1
SCHEMBL14634163 0.68 RIPK2 (0.48) RIPK2KCNH2GAKLCKTGFBR1
SCHEMBL14635393 0.68 PDGFRB (0.33) RIPK2KCNH2PDGFRBFGFR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 PIK3CA 78/4885RIPK2 443/4885KCNH2 1306/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 PIK3CA 99/4885RIPK2 432/4885KCNH2 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.